Johnson & Johnson Finalizes $3.05B Halda Therapeutics Acquisition to Expand Prostate Cancer Pipeline

New Brunswick, NJ, December 29, 2025 (PR Newswire) -- Johnson & Johnson has completed its $3.05 billion all-cash acquisition of Halda Therapeutics, adding a differentiated oral oncology platform to its Innovative Medicine portfolio. The deal brings HLD-0915, a once-daily oral prostate cancer therapy designed to overcome resistance mechanisms through Halda’s proprietary RIPTAC™ technology. Beyond prostate cancer, the platform also supports earlier-stage programs across breast, lung, and other solid tumors, with potential applications outside oncology.

Read full article here.